uACR and eGFR: Two Tests That Reveal Hidden Kidney and Cardiovascular Risk

A blood creatinine result can look normal while urine already contains more albumin than expected. The reverse can also happen: little albuminuria alongside a reduced estimated filtration rate.

Kidney and cardiovascular risk therefore cannot be read from one number. The two foundational tests are estimated glomerular filtration rate (eGFR), calculated from a blood test, and urine albumin-to-creatinine ratio (uACR). Together they help detect chronic kidney disease, grade risk and decide what needs confirmation, monitoring or treatment.

The first ESC guideline dedicated to cardiovascular disease and chronic kidney disease, published in August 2026, recommends eGFR and albuminuria testing in every person with cardiovascular disease. That does not turn one result into a diagnosis or an automatic prescription.

What uACR measures—and why it is not the same as creatinine

Albumin is an abundant blood protein. The glomerular filter normally retains it; increased passage into urine is called albuminuria. uACR divides urine albumin concentration by urine creatinine concentration and is usually reported as mg/g or mg/mmol.

The ratio partly adjusts for urine concentration. A spot sample is therefore generally sufficient, without a 24-hour collection as the first test. A first-morning void is preferred because it varies less, although a random sample is acceptable.

eGFR answers a different question. It is usually calculated from serum creatinine, age and sex with a validated equation. It estimates filtration; it does not directly measure albumin loss. Serum creatinine also reflects muscle mass, diet and clinical stability, so it may overestimate filtration in someone with very low muscle mass and underestimate it in a highly muscular person.

When precision could change a decision and creatinine is likely to be misleading, the 2024 KDIGO guideline recommends considering an estimate that combines creatinine and cystatin C. Even that equation does not replace clinical context.

How to read A1-A3 and G1-G5 without diagnosing yourself from a table

KDIGO classifies kidney disease by cause, GFR category and albuminuria category—the CGA system. The table guides risk; it does not identify the cause or prove chronicity on its own.

Marker	Category	Result	Clinical reading
uACR	A1	<30 mg/g (<3 mg/mmol)	Normal to mildly increased
uACR	A2	30-300 mg/g (3-30 mg/mmol)	Moderately increased; confirm persistence
uACR	A3	>300 mg/g (>30 mg/mmol)	Severely increased; faster assessment needed
eGFR	G1 / G2	≥90 / 60-89 mL/min/1.73 m²	Does not define CKD without albuminuria or another damage marker
eGFR	G3a / G3b	45-59 / 30-44	Mild-to-moderate or moderate-to-severe reduction
eGFR	G4 / G5	15-29 / <15	Severe reduction / kidney failure

Two nuances prevent unnecessary alarm. First, G1 or G2 does not mean CKD without albuminuria, structural abnormalities or another marker of damage. Second, A2 or A3 with an eGFR above 60 can represent CKD when it persists.

Thresholds are clinical conventions and risk is continuous. uACR results of 29 and 31 mg/g do not describe opposite biology. Trend, reason for testing, blood pressure, diabetes, cardiovascular disease and other findings all matter.

How large is the risk signal?

uACR and eGFR are not kidney-only markers. In an individual-participant meta-analysis published in JAMA, the creatinine-based analysis included 27,503,140 people from 114 cohorts and the albuminuria analysis included 9,067,753. Lower eGFR and higher uACR were each independently associated with greater risk across ten kidney and cardiovascular outcomes.

One comparison gives the signal scale: among people with uACR below 10 mg/g, an eGFR of 45-59 versus 90-104 mL/min/1.73 m² was associated with more hospitalizations—adjusted HR 1.3 (95% CI 1.2-1.3) and an adjusted excess of 22 hospitalizations per 1,000 person-years. This is an observational association, not the number of events a test or treatment will prevent for an individual.

Risk rises as the map moves simultaneously toward lower eGFR and higher albuminuria. That intersection explains why blood creatinine alone can miss information—and why uACR should not become a verdict either.

Who is most likely to benefit from both tests?

Testing has high priority in diabetes, hypertension, cardiovascular disease—including coronary disease, heart failure, peripheral artery disease or stroke—previous acute kidney injury, known kidney disease and selected family histories. KDIGO recommends both markers in people at risk; the 2026 ESC guideline recommends joint screening in all established cardiovascular disease.

In diabetes, assessment is generally at least annual: from diagnosis in type 2 diabetes and after five years of type 1 diabetes. In hypertension, cardiovascular disease, reduced eGFR, hematuria or previous albuminuria, frequency depends on whether a result could change stage or treatment.

This is not a reason for every healthy adult to order uACR every few months. In lower-risk people, population screening and the right interval depend on the health system, age, capacity to act and personal goals. As with a coronary calcium score, a test is most useful when it answers a defined clinical question.

A practical testing protocol: confirm chronic disease without missing an acute problem

1. Start with the pair. Blood creatinine with eGFR plus quantitative spot uACR; a protein dipstick does not replace laboratory uACR.
2. Reduce avoidable noise. Keep usual hydration, use a first-morning sample when possible and avoid intense exercise the day before. Report fever, urinary infection, menstruation, visible blood or acute illness.
3. Repeat unexpected results promptly. A new marked eGFR fall or severe albuminuria may need retesting within days or weeks to rule out acute kidney injury; do not wait three months when the problem may be acute.
4. Establish chronicity. In a stable setting, two measurements over at least three months help confirm CKD. Previous results, imaging or history may also document duration.
5. Look for cause and consequences. Review blood pressure, glucose, potassium, urine sediment/hematuria, medication, history and, where indicated, ultrasound or specialist assessment.

Intense exercise, menstruation, hematuria and symptomatic urinary infection can temporarily raise uACR. Fever, dehydration, decompensated heart failure and other acute illnesses also alter interpretation. Repeating a result is not about making an inconvenient number disappear; it separates temporary variation from a persistent signal.

What a confirmed result may change

Situation	Reasonable next step	What to avoid
eGFR ≥60, A1 and no other markers	Retest according to risk; maintain blood pressure, glucose and lifestyle care	Labeling CKD from age or an in-range creatinine alone
One isolated A2 uACR	Review temporary causes and confirm with first-morning urine	Diagnosing chronic damage or buying kidney supplements
Persistent A2/A3 with preserved eGFR	Establish cause, cardiovascular risk and a monitoring/treatment plan	Reassurance based only on apparently normal creatinine
Persistent eGFR <60	Classify G and A, review drug dosing/safety and calculate risk when appropriate	Calling every decline inevitable aging
Abrupt change, oliguria or symptoms	Prompt assessment for acute kidney injury or obstruction	Waiting three months to retest

A persistent result may alter blood pressure targets, cardiovascular prevention, dosing of renally cleared drugs, avoidance of risky combinations or eligibility for cardiorenal therapies. ACE inhibitors or ARBs, SGLT2 inhibitors, finerenone and GLP-1 receptor agonists have different indications depending on diabetes, heart failure, eGFR, uACR, potassium and tolerance.

No uACR value lets someone select medication on their own. Some treatments cause an expected early eGFR dip or require potassium monitoring; others need dose adjustment or should be avoided at particular levels. The decision belongs within a full review, just as it does for ApoB, lipoprotein(a) or starting a statin after 70.

Limitations and common interpretation errors

• One number does not reveal the cause. Diabetes and hypertension are common, but glomerular disease, medication, obstruction, vascular disease and other causes need different pathways.
• uACR does not measure filtration. Albuminuria and kidney function complement one another; they are not interchangeable.
• eGFR is an estimate. Extreme muscle mass, frailty, amputation, pregnancy, diet and acute change can reduce accuracy.
• The ratio depends on urine creatinine. Sex, body size and creatinine generation can shift uACR, especially near a threshold.
• Lowering a marker does not guarantee an equal clinical benefit. Trends inform response and prognosis, but kidney failure, cardiovascular events, function and quality of life remain the outcomes that matter.

The best interpretation is not simply “high or normal” but a trajectory: why the test was ordered, the conditions under which it was collected, whether it persists, which GFR category accompanies it and which decision changes. The same principle prevents longevity biomarkers from becoming a collection of numbers.

Red flags that should not wait for routine retesting

Seek prompt medical assessment for a marked reduction in urine, visible blood, new leg or eyelid swelling, breathlessness, fever with flank pain, persistent vomiting or diarrhea, very high blood pressure or general deterioration. A sudden eGFR fall requires assessment for acute kidney injury, medication effects, dehydration or obstruction—not a CKD label.

Chest pain, severe breathlessness, confusion, fainting or no urine warrants emergency care. Sudden stroke or TIA symptoms remain an emergency regardless of kidney status.

Frequently asked questions about uACR and eGFR

What is the urine albumin-creatinine ratio, or uACR?

It measures urine albumin relative to urine creatinine in a spot sample. The ratio partly adjusts for how dilute or concentrated the urine is and can identify albumin amounts that a standard protein dipstick may miss.

Can I have albuminuria with normal creatinine and eGFR?

Yes. Persistent albuminuria can occur while eGFR remains 60 mL/min/1.73 m² or higher. That is why guidelines pair eGFR with uACR in people at risk; neither test replaces the other.

Does a uACR above 30 mg/g mean I have chronic kidney disease?

Not from one sample. A uACR of 30 mg/g or higher falls within A2 or A3, but CKD requires persistence for at least three months or other evidence of chronicity. Intense exercise, fever, urinary infection, menstruation, hematuria or acute illness can also raise a result temporarily.

What do A1, A2 and A3 mean?

A1 is uACR below 30 mg/g, A2 is 30-300 mg/g, and A3 is above 300 mg/g. They are albuminuria and risk categories, not a standalone measure of kidney function. They must be combined with G1-G5, cause and trajectory.

How should I prepare for a uACR test?

A first-morning sample is preferred, although a random sample can be used. Keep your usual hydration and ask whether to postpone after intense exercise or during fever, urinary infection, menstruation or acute decompensation. Do not stop medication on your own.

When should uACR and eGFR be repeated?

A new, severe or unexpected change may need repetition within days or weeks to rule out acute kidney injury. To establish chronicity, the ESC guideline recommends two measurements over at least three months. Later frequency depends on stage, cause, treatment and risk.

Does a high uACR mean I need medication?

Not automatically. It may alter blood pressure, diabetes and cardiovascular management, medication review or eligibility for cardiorenal therapies, but decisions also depend on eGFR, potassium, diagnosis, comorbidity and tolerance. There is no single threshold for every drug.

When is a kidney result urgent?

Seek prompt assessment for a sudden eGFR fall, much less urine, visible blood, new swelling, persistent vomiting or diarrhea, fever with flank pain, very high blood pressure or breathlessness. Chest pain, severe breathlessness, confusion or no urine warrants emergency care.

Sources

1. European Society of Cardiology and European Renal Association. 2026 Guideline on cardiovascular disease and chronic kidney disease.
2. KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2024.
3. CKD Prognosis Consortium. eGFR, albuminuria and adverse outcomes: individual-participant meta-analysis. JAMA. 2023.
4. NIDDK. Quick Reference on UACR & GFR.
5. National Kidney Foundation. Urine Albumin-Creatinine Ratio.
6. American Kidney Fund. Urine test: uACR. Updated September 2026.

Method: narrative review of the 2026 ESC guideline, KDIGO 2024, an individual-participant meta-analysis and official patient resources. Prognostic association is separated from treatment effect, and one abnormal sample is not presented as CKD. Sources and English-language search results checked 24 September 2026. This article is educational and does not replace medical assessment.

At Progevita, preventive medicine is not about accumulating tests. It is a process of listening, measuring, interpreting and measuring again when the result may change a decision. If uACR and eGFR tell different stories, a joined-up clinical review can order causes, risk, habits and follow-up without turning one result into an identity.